Cytokine-directed therapies in multiple sclerosis and experimental autoimmune encephalomyelitis (Q41745135)

8 October 2017

1 reference

title

Cytokine-directed therapies in multiple sclerosis and experimental autoimmune encephalomyelitis (English)

1 reference

8 October 2017

0 references

Ruuls SR

1

1 reference

PubMed ID

9553778

8 October 2017

Sedgwick JD

series ordinal

2

1 reference

8 October 2017

1 February 1998

1 reference

Immunology & Cell Biology

8 October 2017

1 reference

8 October 2017

76

1 reference

8 October 2017

1

1 reference

8 October 2017

65-73

1 reference

Mechanisms of immune injury in multiple sclerosis

8 October 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Steroids in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Interleukin-10 prevents experimental allergic encephalomyelitis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Tolerogenic forms of auto-antigens and cytokines in the induction of resistance to experimental allergic encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Anti?tumor necrosis factor therapy abrogates autoimmune demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Immune response to chemically modified flagellin. II. Evidence for a fundamental relationship between humoral and cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Immune response to chemically modified flagellin. 3. Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

The expanding universe of T-cell subsets: Th1, Th2 and more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Th1 and Th2 subsets: paradigms lost?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

The T lymphocyte in experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Soluble tumor necrosis factor receptor inhibits interleukin 12 production by stimulated human adult microglial cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Oral tolerance: immune mechanisms and treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

T helper 2 (Th2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Virus interference. I. The interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Immune interferon: a pleiotropic lymphokine with multiple effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Interferon-beta impairs induction of HLA-DR antigen expression in cultured adult human astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Contrasting effect of alpha/beta- and gamma-interferons on expression of macrophage Ia antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin 2 and interleukin 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Effects of cloned interferon alpha 2 in normal volunteers: febrile reactions and changes in circulating corticosteroids and trace metals

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Circulating adhesion molecules and inflammatory mediators in demyelination: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Interferon-beta downregulates expression of VLA-4 antigen and antagonizes interferon-gamma-induced expression of HLA-DQ on human peripheral blood monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Tumour necrosis factor and lymphotoxin: molecular aspects and role in tissue-specific autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

A critical role for lymphotoxin in experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.1998.00715.X

10.1046/J.1440-1711.1998.00715.X

21 January 2018

Identifiers

DOI

1 reference

8 October 2017

1 reference

PubMed ID

9553778